The present invention relates to a Siphoviridae bacteriophage Lac-BRP-1 that is isolated from the nature and can kill Lactobacillus brevis cells specifically, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12659BP), and a method for preventing and treating the contaminations of Lactobacillus brevis by using the composition comprising the bacteriophage as an active ingredient.

The invention relates to a non-invasive imaging method of bacteria. One embodiment comprises labeling the bacteria with a radioisotope, then delivering it to the gut of a human or animal. Another embodiment is to label bacteriophages, then administer them to a human or animal, so that they infect (and thus co-localize with) bacteria already resident in the human or animal. The bacteriophage can then be imaged, showing the location of the resident bacteria of interest. In another embodiment, the invention is related more generally to the labelling of bacteria or bacteriophages with a radio-metal or radioisotope to render the labeled gut bacteria and the bacteria in the body visible to nuclear medicine PET and SPECT imaging guided by functional/structural MRI and/or CT imaging. In another embodiment, the invention is related more generally to the labelling of bacteria or bacteriophages (both or just one) with a radio-metal or radioisotope to render the gut bacteria and the bacteria in the body visible to nuclear medicine PET and SPECT imaging guided by functional/structural MRI and/or CT imaging or visible by MRI alone or in combination with either PET or SPECT.

Bacteriophages are provided that infect strains of Enterococcus faecalis, an opportunistic bacterial pathogen that causes human disease. Also provided are methods of treating Enterococcus faecalis by therapeutic administration of such bacteriophages.

Provided is a novel bacteriophage ΦCJ21 (KCCM11363P). In addition, the present invention relates to an antibacterial composition including the bacteriophage ΦCJ21 (KCCM11363P) as an active ingredient. Further, provided is a method of preventing and/or treating infectious diseases by Clostridium perfringens in animals except for humans using the bacteriophage ΦCJ21 (KCCM11363P) or the antibacterial composition containing the bacteriophage ΦCJ21 (KCCM11363P) as an active ingredient.

The present disclosure relates to CRISPR-Cas10 systems and methods for phage genome editing.

Provided is a novel bacteriophage ΦCJ22 (KCCM11364P). In addition, provided is an antibacterial composition containing the bacteriophage ΦCJ22 (KCCM11364P) as an active ingredient. Further, provided is a method of preventing and/or treating infectious diseases caused by Clostridium perfringens in animals except for humans by using the bacteriophage ΦCJ22 (KCCM11364P) or an antibacterial composition containing the bacteriophage ΦCJ22 (KCCM11364P) as an active ingredient.

The invention provides a composition (e.g., pharmaceutical composition) comprising a combination of two or more phages, wherein the phages are two or more of: (a) phage D29; (b) phage AdephagiaΔ41Δ43; (c) phage FionnbharthΔ47; (d) phage Fred313cpm-1; and (e) phage MuddyHRM.sup.N0052-1; and a pharmaceutically acceptable carrier. The invention provides a method of treating, reducing, or preventing a disease caused by Mycobacterium tuberculosis in a mammal comprising administering a pharmaceutical composition comprising a combination of two or more phages wherein the phages are two or more of: (a) phage D29; (b) phage AdephagiaΔ41Δ43; (c) phage FionnbharthΔ47; (d) phage Fred313cpm-1; and (e) phage MuddyHRM.sup.N0052-1; and a pharmaceutically acceptable carrier. The composition can be administered alone or in combination with one or more antibiotics, wherein the length of treatment is reduced as compared to the length of treatment with one or more antibiotics alone.

The present disclosure relates generally to bacterial delivery vehicles for use in efficient transfer of a desired payload into a target bacterial cell. More specifically, the present disclosure relates to bacterial delivery vehicles with desired host ranges based on the presence of a chimeric receptor binding protein (RBP) composed of a fusion between the N-terminal region of a RBP derived from a lambda-like bacteriophage and the C-terminal region of a different RBP, and/or the presence of an engineered branched receptor binding multi-subunit polypeptides (“branched-RBP”).

The present invention relates to Siphoviridae bacteriophage Lac-GAP-3 (Accession Number KCTC 12816BP) having the ability to specifically kill Lactococcus garvieae bacteria and a genome represented by SEQ ID NO: 1 and isolated from nature, and a method for prevention and treatment of Lactococcus garvieae bacterial infection by using a composition containing the same bacteriophage as an effective ingredient.

An antibacterial formulation having a mixture of bacteriophages with lytic activity against strains of Salmonella spp. and a pharmaceutically and veterinarily acceptable vehicle, pH stabilizer and/or excipients. This formulation is for the prevention and treatment of infectious diseases caused by Salmonella spp. and different serovars; use and method for preventing or treating infectious diseases caused by Salmonella spp. in farm animals by administering the antibacterial formulation to a non-human animal orally.